Hepatitis B virus reactivation associated with anti-neoplastic therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 31-37

  Yeo, Winnie ^a,b   Chan, Henry Ly ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b The Australian National University   (Australia)

Author keywords

Hepatitis B virus; Immunosuppression; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; RITUXIMAB; TENOFOVIR; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL RESISTANCE; ARTICLE; BIOLOGICAL THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL FEATURE; DISEASE COURSE; FULMINANT HEPATIC FAILURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; LIVER CELL CARCINOMA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEROCONVERSION; SERODIAGNOSIS; VIRUS REACTIVATION; VIRUS REPLICATION; WHOLE BODY RADIATION;

EID: 84871671108     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07280.x     Document Type: Article

References (76)

1. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 2004; 350: 1118-1129.
2. Lee W. Hepatitis B infection. N. Engl. J. Med. 1997; 337: 17345-1745.
3. Lok ASF, Lai CL, Wu PC. Hepatitis B virus infection in Chinese families in Hong Kong. Am. J. Epidemiol. 1987; 126: 492-499.
4. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112.
5. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 1996; 2: 1104-1108.
6. Yuki N, Nagaoka T, Yamashiro M etal. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003; 37: 1172-1179.
7. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
8. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev. Med. Virol. 2001; 11: 287-299.
9. Kitano K, Kobayashi H, Hanamura M etal. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region. Eur. J. Haematol. 2006; 77: 255-258.
10. Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ, Bagshawe KD. Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528-530.
11. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
12. Yeo W, Chan PKS, Zhong S etal. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol. 2000; 62: 299-307.
13. Yeo W, Lam KC, Zee B etal. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol. 2004; 15: 1661-1666.
14. Yeo W, Chan PKS, Hui P etal. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy: a prospective study. J. Med. Virol. 2003; 70: 553-561.
15. Yeo W, Mo FKF, Chan SL etal. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007; 45: 1382-1389.
16. Lau GKK, Lee CK, Liang R. Hepatitis B virus infection and allogeneic bone marrow transplantation. Crit. Rev. Oncol. Hematol. 1999; 31: 71-76.
17. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol. 1999; 17: 394-398.
18. Nagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol. Res. 2003; 26: 293-301.
19. Jang JW, Kwon JH, You CR etal. Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma. Antivir. Ther. 2011; 16: 969-977.
20. Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support. Care Cancer 2004; 12: 191-196.
21. Kris MG, Hesketh PJ, Herrstedt J etal. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support. Care Cancer 2005; 13: 85-96.
22. Kumagai K, Takagi T, Nakamura S etal. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol. 1997; 8 (Suppl. 1): 107-109.
23. De Vita VT Jr, Hubbard SM, Longo DL. The chemotherapy of lymphoma- looking back, moving forward: the Richard and Hinda Rosenthal Foundation award Lecture. Cancer Res. 1987; 47: 5810-5824.
24. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large cell lymphoma: results of a tree-structured survival analysis. J. Clin. Oncol. 1990; 8: 963-977.
25. Bonadonna G, Valagussa A, Moliterni A etal. Adjuvant cyclophosphamide, and fluorouracil in node-positive breast cancer. The results of 20 years follow-up. N. Engl. J. Med. 1995; 332: 901-906.
26. Citron ML, Berry DA, Cirrincione C etal. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003; 21: 1431-1439.
27. Leung NWY, Tam JSL, Lau GTC, Leung TWT, Lau WY, Li AKC. Hepatitis B virus DNA in peripheral blood leucocytes-a comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994; 73: 1143-1148.
28. Borentain P, Colson P, Coso D etal. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J. Viral Hepat. 2010; 17: 807-815.
29. Goyama S, Kanda Y, Nannya Y etal. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation. Leuk. Lymphoma 2002; 43: 2159-2163.
30. Webster A, Brenner MK, Prentice HG, Griffiths PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989; 4: 207-208.
31. Lau GKK, Leung YH, Fong DYT etal. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324-2330.
32. Cooper A, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol. 2010; 149: 3-13.
33. Osterborg A, Dyer MJ, Bunjes D etal. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol. 1997; 15: 1567-1574.
34. Lazdina U, Alheim M, Nyström J etal. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J. Gen. Virol. 2003; 84: 139-141.
35. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N. Engl. J. Med. 2001; 345: 1000.
36. Hanbali A, Khaled Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am. J. Hematol. 2009; 84: 195.
37. Matsue K, Kimura S, Takanashi Y etal. Reactivation of hepatitis B Virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116: 4769-4776.
38. Francisci D, Falcinelli F, Schiaroli E etal. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38: 58-61.
39. Bedognetti D, Zoppoli G, Sertoli MR etal. Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era. Int. J. Hematol. 2010; 91: 342-344.
40. Koo YX, Tan DSW, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010; 116: 115-121.
41. Pei SN, Ma MC, Wang MC etal. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann. Hematol. 2012; 91: 1007-1012. published online. DOI: 10.1007/s00277-012-1405-6.
42. Hui CK, Cheung WW, Zhang HY etal. Kinetics and risk of De Novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68.
43. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008; 93: 951.
44. Fukushima N, Mizuta T, Tanaka M etal. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann. Oncol. 2009; 20: 2013-2017.
45. Yeo W, Chan V, Leung NWY etal. Hepatitis B Virus reactivation in lymphoma patients with history of resolved hepatitis B being treated with or without rituximab-containing anti-cancer therapy. J. Clin. Oncol. 2008; 27: 605-611.
46. Ji D, Cao J, Hong X etal. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study. Eur. J. Haematol. 2010; 85: 243-250.
47. Evens AM, Jovanovic BD, Su YC etal. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: metaanalysis and examination of FDA safety reports. Ann. Oncol. 2011; 22: 1170-1180.
48. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod. Rheumatol. 2012; [Epub ahead of print] DOI 10.1007/s10165-012-0709-7.
49. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011; 33: 619-633.
50. Yeo W, Mok TS, Zee B etal. Phase III study of adriamycin versus cisplatin/interferon α-2b/adriamycin/fluorouracil combination chemotherapy for inoperable hepatocellular carcinoma. J. Natl Cancer Inst. 2005; 97: 1532-1538.
51. Hoofnagle JH, Davis GL, Pappas SC etal. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 1986; 104: 12-17.
52. Borg ter F, Smorenburg S, De Man RA, Rietbroek RC, Chamuleau RAFM, Jones EA. Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig. Dis. Sci. 1998; 43: 2267-2270.
53. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma (letter). Blood 1996; 87: 1202.
54. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma. Ann. Oncol. 1998; 9: 385-387.
55. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br. J. Haematol. 2002; 116: 166-169.
56. Hsu C, Hsiung CA, Su IJ etal. Revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-853.
57. Yeo W, Chan PKS, Chan HLY etal. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J. Med. Virol. 2001; 65: 473-477.
58. Lok ASF, Wu PC, Lai CL etal. A controlled trial of interferon with or without prednisolone priming for hepatitis B. Gastroenterology 1992; 102: 2091-2097.
59. Cheng AL, Hsiung CA, Su IJ etal.; Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320-1328.
60. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann. Hematol. 2004; 83: 270-275.
61. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996; 78: 2210-2215.
62. Lau GK, He ML, Fong DY etal. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702-709.
63. Rossi G, Pelizzari A, Motta M etal. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol. 2001; 115: 58-62.
64. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396.
65. Lau GK, Yiu HH, Fong DY etal. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742-1749.
66. Yeo W, Chan PKS, Ho WM etal. Lamivudine for the prevention of hepatitis B virus reactivation in HBsAg seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin. Oncol. 2004; 15: 1661-1666.
67. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2007; 28: 28-38.
68. Loomba R, Rowley A, Wesley R etal. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008; 148: 519-528.
69. Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology 2007; 46: 1049-1056.
70. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
71. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
72. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
73. National Comprehensive Cancer Network. NCCN Clincial Practice gudeleines in Oncology-Non-Hodgkin's lymphoma (Version 2.2012). 2012; 139. Cited 30 June 2012. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF.
74. Wang C, Fan R, Sun J, Hou JL. Prevention and management of drug resistant HBV infection. J. Gastroenterol. Hepatol. 2012; 27: 1432-1440.
75. Zurawska U, Hicks LK, Woo G etal. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J. Clin. Oncol. 2012; 30: 3167-3173.
76. Liang RHS, Lok ASF, Lai CL, Chan TK, Todd O, Chiu EKW. Hepatitis B infection in patients with lymphomas. Hematol. Oncol. 1990; 8: 261-270.